374 related articles for article (PubMed ID: 29038471)
1. Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.
Novak JS; Hogarth MW; Boehler JF; Nearing M; Vila MC; Heredia R; Fiorillo AA; Zhang A; Hathout Y; Hoffman EP; Jaiswal JK; Nagaraju K; Cirak S; Partridge TA
Nat Commun; 2017 Oct; 8(1):941. PubMed ID: 29038471
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
3. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
4. Restoring Dystrophin Expression with Exon 44 and 53 Skipping in the DMD Gene in Immortalized Myotubes.
Echigoya Y; Yokota T
Methods Mol Biol; 2023; 2587():125-139. PubMed ID: 36401027
[TBL] [Abstract][Full Text] [Related]
5. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
6. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
7. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
8. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Yin H; Moulton HM; Betts C; Seow Y; Boutilier J; Iverson PL; Wood MJ
Hum Mol Genet; 2009 Nov; 18(22):4405-14. PubMed ID: 19692354
[TBL] [Abstract][Full Text] [Related]
9. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
10. Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.
Vila MC; Novak JS; Benny Klimek M; Li N; Morales M; Fritz AG; Edwards K; Boehler JF; Hogarth MW; Kinder TB; Zhang A; Mazala D; Fiorillo AA; Douglas B; Chen YW; van den Anker J; Lu QL; Hathout Y; Hoffman EP; Partridge TA; Nagaraju K
J Pathol; 2019 Jul; 248(3):339-351. PubMed ID: 30883742
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
13. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.
Aoki Y; Nagata T; Yokota T; Nakamura A; Wood MJ; Partridge T; Takeda S
Hum Mol Genet; 2013 Dec; 22(24):4914-28. PubMed ID: 23882132
[TBL] [Abstract][Full Text] [Related]
14. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.
Lee J; Echigoya Y; Duddy W; Saito T; Aoki Y; Takeda S; Yokota T
PLoS One; 2018; 13(5):e0197084. PubMed ID: 29771942
[TBL] [Abstract][Full Text] [Related]
15. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
[TBL] [Abstract][Full Text] [Related]
16. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
[TBL] [Abstract][Full Text] [Related]
17. [Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].
Takeda S
Rinsho Shinkeigaku; 2009 Nov; 49(11):856-8. PubMed ID: 20030230
[TBL] [Abstract][Full Text] [Related]
18. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.
Malerba A; Thorogood FC; Dickson G; Graham IR
Hum Gene Ther; 2009 Sep; 20(9):955-65. PubMed ID: 19469709
[TBL] [Abstract][Full Text] [Related]
19. Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.
Chen S; Le BT; Chakravarthy M; Kosbar TR; Veedu RN
Sci Rep; 2019 Apr; 9(1):6078. PubMed ID: 30988454
[TBL] [Abstract][Full Text] [Related]
20. Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo.
Hu Y; Wu B; Zillmer A; Lu P; Benrashid E; Wang M; Doran T; Shaban M; Wu X; Lu QL
Mol Ther; 2010 Apr; 18(4):812-8. PubMed ID: 20087314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
